15353-j-veluchamy

6 General discussion and Future Prospects | 155 Advanced solid tumors (NCT01946789), multiple myeloma (NCT02099539), HIV patients (NCT02191098), with nivolumab in NSCLC (NCT02523469), with rituximab (NCT02384954) in B cell Non-Hodgkin Lymphoma (NHL) (NCT02384954), with (BCG) in Non-Muscle Invasive Bladder Cancer (NCT02138734), with chemotherapy drugs gemcitabine and Nab-paclitaxel in advanced pancreatic cancer (NCT02559674). Phase I/II Solid tumors and Multiple Myeloma Preclinical Solid tumors and haematological malignancies Preclinical Disease target Product stage As monotherapy (Phase II, NCT02399917), with nivolumab (Phase I, NCT01592370), with ipililumab (Phase I, NCT01750580), 5-azacytidine (Phase I, NCT02399917), with nivolumab + 5-azacytidine (Phase II, NCT02599649), with elotuzumab (NCT02252263) and with rituximab (Phase I, NCT02481297). Phase I/ II As monotherapy (Phase I/II, NCT02459301, NCT02331875 with cetuximab (NCT02643550), with ibrutinib (NCT02557516) and with durvalumab (NCT02671435). Phase I/II As monotherapy in cutaneous T cell lymphoma (NCT02593045) Phase I Solid tumors and haematological malignancies Preclinical Altor Bi sciences corporation ALT-803 IL-15 super agonist reported to stably express IL-15. Increases NK cell proliferation in vivo , also enhances expansion of migratory NK subsets. NOXXON Pharma NOX-A12 Functions as chemokine receptor CXCL12 inhibitor, enables the release of CXCL12 from the surface of tumor stromal cells, thus facilitating migration of tumor cells towards NK cells. AvidBi tics MicAbody proteins Dual ro e: binds to NKG2D receptor in NK cells and to target antigens of interest simultaneously Abbreviations: Killer cell immunoglobulin-like receptors (KIRs), Antibody dependent cell mediated cytotoxicity (ADCC), aNK-activated NK cells, haNK-high affinity NK cells, taNK-target activated NK cells, monoclonal antibodies (mAbs), Nicotinamide (NAM), Chimeric antigen receptors (CARs), Epithelial cell adhesion molecule (EpCAM), Acute Myeloid Leukemia (AML), Killer cell immunoglobulin like receptor two domains long cytoplasmic tail 1-3 (KIR2DL1-3), Killer cell immunoglobulin like receptor three domains long cytoplasmic tail 2 (KIR3DL2). MHC class-I-chain related protein A and B (MICA/MICB), Human immunodeficiency virus (HIV), non -small-cell lung cancer (NSCLC), Bacillus Calmette Guerin (BCG). Comp ny NK cell product Product charact ristics In ate Ph rma S. A. Lirilumab mAb to block NK cell inhibitory signalling from KIRs (KIR2DL1 -3). Monalizumab mAb to block NK cell inhibitory receptor NKG2A IPH4102 mAb to block NK cell inhibitory receptor KIR3DL2 IPH4301 mAb to target NKG2D ligands MICA/MICB and it also mediates ADCC with NK cells